Richard Quinn is a freelance writer in New Jersey.
Related Articles
Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Rheumatologist, Cyclist Michael Weinblatt, MD, Tours America on Two Wheels
Bonus: Listen to excerpts from our conversation with Dr. Weinblatt. Michael Weinblatt, MD, is the co-director of clinical rheumatology at Brigham and Women’s Hospital in Boston, a professor of medicine at Harvard Medical School, past president of the American College of Rheumatology, and co-director of the ACR Winter Rheumatology Symposium at Snowmass, Colo. ad goes…
Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?
As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…